Schizophrenia Trial, Recruiting NCT06978803 Sponsor: Douglas Mental Health University Institute Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06978803
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who speak English or French (participants are paired with others who speak the same language)
  • People between 18 and 60 years old
  • People who have been diagnosed by their psychiatrist with schizophrenia or schizoaffective disorder, based on standard diagnostic guidelines (DSM-5)
  • People whose illness started less than 5 years ago, measured from when they first began taking antipsychotic medication

Who may not be able to join:

  • People whose main diagnosis is alcohol or drug abuse or addiction (however, having a substance use issue alongside a primary diagnosis of a psychotic disorder is not a reason for exclusion)
  • People who have a serious medical condition that could itself explain psychotic symptoms
  • People who have a history of, or currently have, a neurological condition that affects their ability to produce speech
  • People with an IQ below 70, or who have a developmental condition such as autism

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lena Palaniyappan, MD, PhD, Douglas Mental Health University Institute

Phone: 5147616131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Douglas Mental Health University Institute
Registry
ClinicalTrials.gov
Start date
16 January 2024
Est. completion
22 October 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Inter-brain phase synchronization using Phase Locking Index via hyperscanning during communication

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov